A Spanish Medical Record Review of Adults With Relapsed or Refractory CD30+ Malignancies When Re-treated With Brentuximab-vedotin

NCT04998331 · clinicaltrials.gov ↗

COMPLETED

Status

51

Enrollment

INDUSTRY

Sponsor class

Conditions

Hodgkin Disease
Lymphoma, T-Cell, Cutaneous

Interventions

OTHER: No Intervention

Sponsor

Takeda